Kalaris Therapeutics Inc

NASDAQ:KLRS

Biotechnology

Healthcare
$2.30 +3.52%

+$0.16 today

Market cap
$54.75M
Beta
0.14
P/E (TTM)
-2.5
EPS (TTM)
-$1.86
52W Low $2.14High $11.88

Volume 0.07M

Average 0.08M

KLRS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Kalaris Therapeutics IncNASDAQ: KLRS

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 23.72M shares rose 485.3% year over year, ahead of the +341.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 3.6% from the prior quarter. Over 3 fiscal years it compounded at +66.1% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +485.3% holds above the trailing-twelve-month pace of +341.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
23.72M+3.6% QoQ
Last fiscal yearDec 2025
15.27M+204.8% YoY
LTMMar 2026
21.01M+341.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+485.3%——
1 year+204.8%——
3-year CAGR+66.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
15.27M USD
Year-over-year change
+204.8%
4-year CAGR
+53.8%

Weighted Avg Shares vs competitors

How KLRS compares with its peers on the latest reported figures

  • KLRS's LTM Mar 2026 weighted avg shares of 21.01M shares is the 7th highest of the 9 companies compared; the peer median is 62.21M shares.
  • Its year-over-year change of +341.4% is the highest of 9, against a peer median of +3.3%.
  • Over three fiscal years its annual growth of +66.1% compares with a peer median of +13.3%.
KLRS Competitors Peer median
Weighted Avg Shares for KLRS and competitors
Company Period LTM YoY 3-year CAGR
CNTXContext Therapeutics Inc.LTM Mar 202694.36M +30.6%+81.3%
STTKShattuck Labs, Inc.LTM Mar 202684.8M +66.7%+18.0%
OVIDOvid Therapeutics Inc.LTM Mar 202674.41M +4.8%+1.5%
IFRXInflaRx N.V.LTM Mar 202668.77M +14.6%+15.0%
CNTBConnect Biopharma Holdings LimitedFY202555.66M +0.8%+0.4%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 202624.5M +1.8%+11.6%
KLRSKalaris Therapeutics IncLTM Mar 202621.01M +341.4%+66.1%
IMAImageneBio IncLTM Mar 202619.79M -59.0%-48.8%
STROSutro Biopharma, Inc.LTM Mar 20266.42M -22.0%+18.8%
Peer median (excluding KLRS) 62.21M+3.3%+13.3%

Competitors are the stored peer set for KLRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue1.12M00013K
Gross Profit(1.12M)000(13K)
Gross Margin—————
Research & Development119.62M11.76M11.71M12.34M30.75M
Selling, General & Admin49.08M2.24M1.76M42.92M15.39M
Operating Expenses168.7M14.01M13.46M55.26M46.14M
Depreciation & Amortization1.12M00013K
EBITDA(169.84M)(15.25M)(14.01M)(58.77M)(41.98M)
EBITDA Margin—————
Operating Income(169.82M)(14.01M)(13.46M)(55.26M)(46.15M)
Operating Margin—————
Interest Income1.32M005.49M0
Interest Expense0235K687K01.44M
Other Income / Expenses(1.14M)(1.48M)(1.24M)(3.51M)2.71M
Income Before Tax(170.96M)(15.49M)(14.7M)(58.77M)(43.44M)
Pre-Tax Margin—————
Income Tax Expense1.01M0000
Net Income(171.96M)(15.49M)(14.7M)(58.77M)(43.44M)
Net Margin—————
EPS (Basic)(63.00)(50.62)(42.09)(11.73)(2.85)
EPS (Diluted)(63.00)(50.62)(42.09)(11.73)(2.85)
Weighted Avg Shares2.73M3.33M4.52M5.01M15.27M
Weighted Avg Shares (Diluted)2.73M3.33M4.52M5.01M15.27M

Kalaris Therapeutics Inc

NASDAQ:KLRS

Intrinsic Alpha fair value

Locked

Current Price

$2.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.